Oral Vancomycin vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
A phase III randomized clinical trial in proportion 2:1 in favor of oral vancomycin
(experimental treatment), multicentric, national, double-blinded, controlled with placebo.
The main objective is to evaluate the effectiveness of treatment with oral vancomycin to
reduce the incidence of Clostridioides difficile infection (CDI) in patients who suffered
previous CDI and who need further hospitalization and treatment with systemic antibiotic
therapy in the 90 days after the first CDI.